Andrew Baum
Stock Analyst at Citigroup
(2.83)
# 1,881
Out of 4,996 analysts
65
Total ratings
72.09%
Success rate
12.97%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $23.76 | +9.43% | 11 | Aug 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $47 | $44.12 | +6.53% | 12 | Aug 1, 2025 | |
| MRK Merck & Co. | Downgrades: Neutral | $115 → $84 | $78.56 | +6.92% | 14 | May 14, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $35.04 | +14.16% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $220.61 | -2.54% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $724.54 | +23.53% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $8.34 | +19.90% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $39.85 | - | 2 | Jul 5, 2017 |
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $23.76
Upside: +9.43%
Bristol-Myers Squibb Company
Aug 1, 2025
Maintains: Neutral
Price Target: $51 → $47
Current: $44.12
Upside: +6.53%
Merck & Co.
May 14, 2025
Downgrades: Neutral
Price Target: $115 → $84
Current: $78.56
Upside: +6.92%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $35.04
Upside: +14.16%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $220.61
Upside: -2.54%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $724.54
Upside: +23.53%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $8.34
Upside: +19.90%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $39.85
Upside: -